{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:19:35Z","timestamp":1784557175051,"version":"3.55.0"},"reference-count":45,"publisher":"Bioscientifica","issue":"1","content-domain":{"domain":["erc.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:p>\n                    Pheochromocytomas (PCCs) are mostly benign tumors, amenable to complete surgical resection. However, 10\u201317% of cases can become malignant, and once metastasized, there is no curative treatment for this disease. Given the need to identify the effective therapeutic approaches for PCC, we evaluated the antitumor potential of the dual-PI3K\/mTOR inhibitor BEZ235 against these tumors. We employed an\n                    <jats:italic>in vivo<\/jats:italic>\n                    model of endogenous PCCs (MENX mutant rats), which closely recapitulate the human tumors. Mutant rats with PCCs were treated with 2 doses of BEZ235 (20 and 30\u2009mg\/kg), or with placebo, for 2 weeks. Treatment with BEZ235 induced cytostatic and cytotoxic effects on rat PCCs, which could be appreciated by both staining the tumors\n                    <jats:italic>ex vivo<\/jats:italic>\n                    with appropriate markers and non-invasively by functional imaging (diffusion-weighted magnetic resonance imaging)\n                    <jats:italic>in vivo<\/jats:italic>\n                    . Transcriptomic analyses of tumors from rats treated with BEZ235 or placebo-identified potential mediators of therapy response were performed.\n                    <jats:italic>Slc6a2<\/jats:italic>\n                    , encoding the norepinephrine transporter (NET), was downregulated in a dose-dependent manner by BEZ235 in rat PCCs. Moreover, BEZ235 reduced\n                    <jats:italic>Slc6a2<\/jats:italic>\n                    \/NET expression in PCC cell lines (MPC) also. Studies of a BEZ235-resistant derivative of the MPC cell line confirmed that the reduction of NET expression associates with the response to the drug. Reduction of NET expression after BEZ235 treatment\n                    <jats:italic>in vivo<\/jats:italic>\n                    could be monitored by positron emission tomography (PET) using a tracer targeting NET. Altogether, here we demonstrate the efficacy of BEZ235 against PCC\n                    <jats:italic>in vivo<\/jats:italic>\n                    , and show that functional imaging can be employed to monitor the response of PCC to PI3K\/mTOR inhibition therapy.\n                  <\/jats:p>","DOI":"10.1530\/erc-16-0324","type":"journal-article","created":{"date-parts":[[2016,11,3]],"date-time":"2016-11-03T21:30:25Z","timestamp":1478208625000},"page":"1-15","update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-1","source":"Crossref","is-referenced-by-count":9,"title":["Targeting PI3K\/mTOR signaling exerts potent antitumor activity in pheochromocytoma in vivo"],"prefix":"10.1530","volume":"24","author":[{"given":"Misu","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninelia","family":"Minaskan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Wiedemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Irmler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Beckers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behrooz H","family":"Yousefi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgios","family":"Kaissis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rickmer","family":"Braren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iina","family":"Laitinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia S","family":"Pellegata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"2016112118451189000_24.1.1.1","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/S0022-3565(24)29276-4","article-title":"Trafficking-dependent and -independent pathways of neurotransmitter transporter regulation differentially involving p38 mitogen-activated protein kinase revealed in studies of insulin modulation of norepinephrine transport in SK-N-SH cells","volume":"299","author":"Apparsundaram","year":"2001","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"2016112118451189000_24.1.1.2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-109-4-267"},{"key":"2016112118451189000_24.1.1.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2008.11.007"},{"key":"2016112118451189000_24.1.1.4","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s10637-015-0218-6","article-title":"A phase 1 study of the sachet formulation of the oral dual PI3K\/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors","volume":"33","author":"Bendell","year":"2015","journal-title":"Investigational New Drugs"},{"key":"2016112118451189000_24.1.1.5","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1242\/jcs.114.8.1439","article-title":"Phosphoinositide 3-kinase signaling pathways","volume":"114","author":"Cantrell","year":"2001","journal-title":"Journal of Cell Science"},{"key":"2016112118451189000_24.1.1.6","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604995"},{"key":"2016112118451189000_24.1.1.7","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.628"},{"key":"2016112118451189000_24.1.1.8","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.2174\/0929867321666140414095605","article-title":"Activation of PI3K\/Akt\/mTOR pathway and dual inhibitors of PI3K and mTOR in endometrial cancer","volume":"21","author":"Chen","year":"2014","journal-title":"Current Medicinal Chemistry"},{"key":"2016112118451189000_24.1.1.9","doi-asserted-by":"publisher","DOI":"10.1055\/s-0029-1220687"},{"key":"2016112118451189000_24.1.1.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2016112118451189000_24.1.1.11","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.00829"},{"key":"2016112118451189000_24.1.1.12","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-10-0211"},{"key":"2016112118451189000_24.1.1.13","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2004-2198"},{"key":"2016112118451189000_24.1.1.14","first-page":"713","article-title":"A phase II study of BEZ235 in patients with everolimus-resistant, advanced pancreatic neuroendocrine tumours","volume":"36","author":"Fazio","year":"2016","journal-title":"Anticancer Research"},{"key":"2016112118451189000_24.1.1.15","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109743200"},{"key":"2016112118451189000_24.1.1.16","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.113.119966"},{"key":"2016112118451189000_24.1.1.17","doi-asserted-by":"publisher","DOI":"10.1111\/eci.12127"},{"key":"2016112118451189000_24.1.1.18","first-page":"789","article-title":"Positron emission tomographic monitoring of dual phosphatidylinositol-3-kinase and mTOR inhibition in anaplastic large cell lymphoma","volume":"7","author":"Graf","year":"2014","journal-title":"OncoTargets and Therapy"},{"key":"2016112118451189000_24.1.1.19","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1902"},{"key":"2016112118451189000_24.1.1.20","doi-asserted-by":"publisher","DOI":"10.1124\/mol.54.5.815"},{"key":"2016112118451189000_24.1.1.21","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23812"},{"key":"2016112118451189000_24.1.1.22","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1836"},{"key":"2016112118451189000_24.1.1.23","doi-asserted-by":"publisher","DOI":"10.1210\/me.2012-1055"},{"key":"2016112118451189000_24.1.1.24","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-013-1132-7"},{"key":"2016112118451189000_24.1.1.25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0288"},{"key":"2016112118451189000_24.1.1.26","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4912"},{"key":"2016112118451189000_24.1.1.27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)67139-5"},{"key":"2016112118451189000_24.1.1.28","doi-asserted-by":"publisher","DOI":"10.1007\/BF03348026"},{"key":"2016112118451189000_24.1.1.29","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-08-0017"},{"key":"2016112118451189000_24.1.1.30","doi-asserted-by":"crossref","first-page":"175352","DOI":"10.1155\/2011\/175352","article-title":"Functional Imaging of Pheochromocytoma with Ga-DOTATOC and C-HED in a genetically defined rat model of multiple endocrine neoplasia","volume":"2011","author":"Miederer","year":"2011","journal-title":"International Journal of Molecular Imaging"},{"key":"2016112118451189000_24.1.1.31","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1003956107"},{"key":"2016112118451189000_24.1.1.32","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4158\/EP13268.RA","article-title":"Genetics, diagnosis, and management of medullary thyroid carcinoma and pheochromocytoma\/paraganglioma","volume":"20","author":"Moraitis","year":"2014","journal-title":"Endocrine Practice"},{"key":"2016112118451189000_24.1.1.33","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-3962"},{"key":"2016112118451189000_24.1.1.34","doi-asserted-by":"publisher","DOI":"10.1530\/JME-12-0028"},{"key":"2016112118451189000_24.1.1.35","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.27675"},{"key":"2016112118451189000_24.1.1.36","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0603877103"},{"key":"2016112118451189000_24.1.1.37","doi-asserted-by":"crossref","first-page":"64","DOI":"10.3389\/fonc.2014.00064","article-title":"Targeting PI3K\/Akt\/mTOR signaling in cancer","volume":"4","author":"Porta","year":"2014","journal-title":"Frontiers in Oncology"},{"key":"2016112118451189000_24.1.1.38","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkl038"},{"key":"2016112118451189000_24.1.1.39","doi-asserted-by":"publisher","DOI":"10.1016\/S0076-6879(06)11009-5"},{"key":"2016112118451189000_24.1.1.40","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-1044"},{"key":"2016112118451189000_24.1.1.41","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-1385"},{"key":"2016112118451189000_24.1.1.42","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1002\/ijc.24925","article-title":"Allelic loss of chromosomes 8 and 19 in MENX-associated rat pheochromocytoma","volume":"126","author":"Shyla","year":"2010","journal-title":"International Journal of Cancer"},{"key":"2016112118451189000_24.1.1.43","doi-asserted-by":"publisher","DOI":"10.1002\/jmri.22167"},{"key":"2016112118451189000_24.1.1.44","doi-asserted-by":"crossref","first-page":"3157","DOI":"10.1210\/en.2016-1108","article-title":"Morphology, biochemistry and pathophysiology of MENX-related pheochromocytoma recapitulate the clinical features","volume":"157","author":"Wiedemann","year":"2016","journal-title":"Endocrinology"},{"key":"2016112118451189000_24.1.1.45","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-15-0413"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/24\/1\/1.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/24\/1\/1.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:53:51Z","timestamp":1784555631000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/erc\/article\/24\/1\/1-15\/26966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":45,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.1530\/erc-16-0324","relation":{},"ISSN":["1351-0088","1479-6821"],"issn-type":[{"value":"1351-0088","type":"print"},{"value":"1479-6821","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}